Skip to main content

Loading market data...

ABBV

AbbVie Inc.

NYSE • United states

$282.68

-$2.74

(-0.96%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:03 GMT+0000

Management
Credibility
Score

AbbVie Inc. (ABBV)

Unavailable

Quotes may be delayed

$499.53B

Market Cap

3,986,994

Volume

79.9

P/E Ratio

2.43%

Div Yield

AbbVie Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

16 Oct 2026

AbbVie Inc. reported A director or senior management change or compensation event

AbbVie Inc. filed an 8-K covering a director or senior management change or compensation event.

6 Oct 2026

AbbVie Inc. reported Operating or financial results

AbbVie Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

3 Sep 2026

AbbVie Inc. reported Regulation FD disclosure

AbbVie Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.

19 Aug 2026

AbbVie Inc. reported Another company event

AbbVie Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

6 Aug 2026

AbbVie Inc. reported Another company event

AbbVie Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$6.57B

Total assets (USD)$135.12B

Shareholders' equity (USD)−$5.94B

Long-term debt (USD)$64.50B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B
PM - Philip Morris International Inc.	$197.46 Yahoo Finance	$307.76B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$16.99B	$6.43B	$3.61B	$2.03	10-Q · 3 Aug 2026
Q1 2026	$15.00B	$3.99B	$695.00M	$0.39	10-Q · 8 May 2026
Q4 2025	$16.62B	$4.54B	$1.82B	$1.02	10-K · 20 Feb 2026
Q3 2025	$15.78B	$1.90B	$186.00M	$0.10	10-Q · 4 Nov 2025
Q2 2025	$15.42B	$4.89B	$938.00M	$0.52	10-Q · 4 Aug 2025
Q1 2025	$13.34B	$3.73B	$1.29B	$0.72	10-Q · 9 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $286.67

1.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

20

⏸️

Hold

4

📉

Sell

0

24 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 10:48 UTC Targets range 225.00–320.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

14

Aug 2026

Donoghoe Nicholas

EVP, CHIEF BUS/STRAT OFFICER

Option exercise

$79.02 per share

32,710 shares

14

Aug 2026

Donoghoe Nicholas

EVP, CHIEF BUS/STRAT OFFICER

Open-market sale

$250.00 per share

32,710 shares

8

May 2026

FALK THOMAS J

Director

Grant or award

Unavailable per share

1,118 shares

8

May 2026

WADDELL FREDERICK H

Director

Grant or award

Unavailable per share

1,118 shares

8

May 2026

Roberts Rebecca B

Director

Grant or award

Unavailable per share

1,118 shares

Top Shareholders

Vanguard Group Inc

180,779,699 shares

1.706% change

12/31/2025

Blackrock, Inc.

149,488,412 shares

-0.803% change

6/30/2026

Vanguard Capital Management Llc

115,396,098 shares

0.449% change

6/30/2026

State Street Corp

82,596,748 shares

1.698% change

6/30/2026

Vanguard Portfolio Management Llc

48,477,996 shares

-2.11% change

6/30/2026

Jpmorgan Chase & Co

47,862,796 shares

-15.648% change

6/30/2026

Geode Capital Management, Llc

46,998,433 shares

0.558% change

6/30/2026

Morgan Stanley

38,901,001 shares

2.326% change

6/30/2026

Capital Research Global Investors

30,101,551 shares

-3.69% change

6/30/2026

Norges Bank

25,554,538 shares

-0.445% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 10:48 UTC· 1 day ago

Research coverage and investment tools

AbbVie Inc. (ABBV) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$282.68 on 19 Oct 2026. That is 91% of the way from its 52-week low of US$190.75 to its 52-week high of US$291.40. It paid US$6.92 a share in dividends over the last 12 months, a dividend yield of 2.43%. The latest ex-dividend date on file is 15 Oct 2026. Its market capitalisation was US$499.53 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$16.99B	$6.43B	$3.61B	$2.03	—	37.9%	$3.11B	10-Q · 3 Aug 2026 (opens in a new tab)
Q1 2026	$15.00B	$3.99B	$695.00M	$0.39	—	26.6%	$3.56B	10-Q · 8 May 2026 (opens in a new tab)
Q4 2025	$16.62B	$4.54B	$1.82B	$1.02	72.6%	27.3%	$4.89B	10-K · 20 Feb 2026 (opens in a new tab)
Q3 2025	$15.78B	$1.90B	$186.00M	$0.10	—	12.1%	$6.64B	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$15.42B	$4.89B	$938.00M	$0.52	—	31.7%	$4.88B	10-Q · 4 Aug 2025 (opens in a new tab)
Q1 2025	$13.34B	$3.73B	$1.29B	$0.72	—	28.0%	$1.40B	10-Q · 9 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/31/2026	$3.65	$3.64	+0.3%
Mar 2026	4/29/2026	$2.65	$2.62	+1.2%
Dec 2025	2/4/2026	$2.71	$2.66	+1.9%
Sep 2025	10/31/2025	$1.86	$1.77	+5.1%

Cash and equivalents: $6.57B
Total assets: $135.12B
Shareholders' equity: −$5.94B
Long-term debt: $64.50B

8-K · 16 Oct 2026 · Management change

AbbVie Inc. reported A director or senior management change or compensation event (opens in a new tab)

AbbVie Inc. filed an 8-K covering a director or senior management change or compensation event.
8-K · 6 Oct 2026

AbbVie Inc. reported Operating or financial results (opens in a new tab)

AbbVie Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 3 Sep 2026

AbbVie Inc. reported Regulation FD disclosure (opens in a new tab)

AbbVie Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.
8-K · 19 Aug 2026

AbbVie Inc. reported Another company event (opens in a new tab)

AbbVie Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 6 Aug 2026

AbbVie Inc. reported Another company event (opens in a new tab)

AbbVie Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER	14 Aug 2026	Option exercise (M)	+32,710	$79.02	Form 4 (opens in a new tab)
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER	14 Aug 2026	Open-market sale (S)	−32,710	$250.00	Form 4 (opens in a new tab)
FALK THOMAS J Director	8 May 2026	Grant or award (A)	+1,118	—	Form 4 (opens in a new tab)
WADDELL FREDERICK H Director	8 May 2026	Grant or award (A)	+1,118	—	Form 4 (opens in a new tab)
Roberts Rebecca B Director	8 May 2026	Grant or award (A)	+1,118	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	180,779,699	1.706%
Blackrock, Inc.	6/30/2026	149,488,412	-0.803%
Vanguard Capital Management Llc	6/30/2026	115,396,098	0.449%
State Street Corp	6/30/2026	82,596,748	1.698%
Vanguard Portfolio Management Llc	6/30/2026	48,477,996	-2.11%
Jpmorgan Chase & Co	6/30/2026	47,862,796	-15.648%
Geode Capital Management, Llc	6/30/2026	46,998,433	0.558%
Morgan Stanley	6/30/2026	38,901,001	2.326%
Capital Research Global Investors	6/30/2026	30,101,551	-3.69%
Norges Bank	6/30/2026	25,554,538	-0.445%

Previous close: 285.42 USD
Day range: 282.59 – 287.93 USD
52-week range: 190.75 – 291.40 USD
Volume: 3,986,994
Market cap: $499.53B
Average volume: 7,233,543
P/E ratio: 79.9
EPS (TTM, diluted): 3.54 USD
Dividends (last 12 months): 6.92 USD
Dividend yield: 2.43%
Ex-dividend date: 15 Oct 2026
Shares outstanding: 1.77B
Beta (5Y monthly): 0.22

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:03 UTC· 2 days ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:13 UTC· 20 minutes ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:13 UTC· 20 minutes ago

P/E is the price ÷ trailing 12-month diluted EPS from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for ABBV yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.